Form D · Biotechnology
AvanSci Bio, L.L.C.
Salt Lake City, UT · CIK 0001533861
Offering snapshot reported May 12, 2014 · SEC filing
- Reported sold
- $160K Offering amount: $200K
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $12K Reported outside-investor minimum
- First sale
- May 2, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 12, 2014 | Initial | $160,000 | No comparison | 4 | SEC filing |
| Mar 13, 2013 | Amendment | $800,000 | $300,000vs Nov 7, 2011 | 7 | SEC filing |
| Nov 7, 2011 | Initial | $500,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-217177
Convertible debt
Source: Form D, filed May 12, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nils B. Adey | Director |
| Robert J Parry | Director, Executive |
| Ronald L. Weiss | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1290 W. 2320 S. Suite D
Salt Lake City, UT, 84119
Salt Lake City, UT, 84119